China-based biopharmaceutical firm CANbridge Pharmaceutical and global open-access biologics technology platform company WuXi Biologics have entered into a partnership for rare disease therapeutics.
The partnership will enable CANbridge to develop and commercialize a portfolio of biotherapeutics for the treatment of rare diseases.
This partnership leverages WuXi Biologics’ drug discovery, development and manufacturing capabilities and CANbridge’s clinical, regulatory and commercial leadership.
This agreement builds on years of new product discovery capabilities established at WuXi Biologics, and the CANbridge team’s years of experience with orphan drug approval processes.
As a result, CANbridge expects to file the first Investigational New Drug (IND) application in a rare disease in China with the lead candidate from this program in 2019.
CANbridge may also develop these therapeutics on a global basis going forward under an exclusive licensing agreement. WuXi Biologics is expected to receive upfront payments, milestone payments and royalties on global sales for these programs.
CANbridge Pharmaceutical founder, chairman and CEO Dr Chris Chen said: “There are huge unmet medical needs in China regarding rare disease diagnosis and treatment.
“I am thrilled that CANbridge will be a trailblazer in this exciting field in China. Being globally recognized for leading technical capabilities, and unparalleled capacities in biologics discovery, development and manufacturing, we are excited to enable CANbridge to become a leader in rare diseases and to collaborate with them to bring the much-needed treatments to Chinese patients.”
WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing.
CANbridge Pharmaceutical Inc. is a China-based biopharmaceutical company accelerating development and commercialization of specialty healthcare products for orphan diseases and targeted cancers, focusing on products that are unavailable or address medical needs that are underserved in the region.
Source: Company Press Release